Rationale: Aspergillus fumigatus (A. fumigatus) in cystic fibrosis (CF) is increasingly recognized. Although allergic bronchopulmonary aspergillosis (ABPA) leads to deterioration of pulmonary function, the effect of A. fumigatus colonization in the absence of ABPA remains unclear. Objectives: To address this, we examined individuals with CF with A. fumigatus who were ABPA negative to identify the effects of itraconazole therapy on Aspergillus-induced lung inflammation. Methods: The effect of A. fumigatus on nuclear vitamin D receptor (VDR) expression was investigated using qRT-PCR and Western blotting. IL-5 and IL-13 levels were quantified by ELISA. The effect of itraconazole was assessed by a combination of high-resolution computed tomography, lung function test, and microbiological analysis. Measurements and Main Results: We demonstrate that A. fumigatus down-regulates VDR in macrophages and airway epithelial cells and that the fungal metabolite gliotoxin (Gt) is the main causative agent. Gt overcame the positive effect of 1,25-OH vitamin D 3 on VDR expression in vitro, resulting in increased IL-5 and IL-13 production. In vivo, A. fumigatus positivity was associated with increased Gt in CF bronchoalveolar lavage fluid and increased bronchoalveolar lavage fluid levels of IL-5 and IL-13. After airway eradication of A. fumigatus with itraconazole, we observed decreased Gt, IL-5 and IL-13, improved respiratory symptoms, and diminished high-resolution computed tomography mosaic pattern consistent with sustained pulmonary function. Conclusions: This study provides a rationale for the therapeutic effect of itraconazole and implied that the therapeutic potential of vitamin D supplementation in preventing ABPA is only feasible with concurrent elimination of A. fumigatus to permit VDR expression and its positive functional consequences.
. Moreover, exposure of cystic fibrosis transmembrane conductance regulator (CFTR)-deficient mice to A. fumigatus antigens leads to a severe pulmonary Th2-biased inflammatory phenotype, suggesting that in CF, even in the absence of ABPA, A. fumigatus acts unfavorably (8) . In addition, vitamin D deficiency has been proposed as a risk factor for CF-ABPA as reduced levels of IL-5 and IL-13 expression were recorded after in vitro treatment with vitamin D (9) . Further support for this theory is provided by research illustrating that deletion of vitamin D receptor (VDR) results in elevated IL-5 and IL-13 production (10) and pulmonary inflammation (11) .
The role of A. fumigatus colonization in the absence of ABPA remains a subject of uncertainty. It has been shown that pulmonary radiological abnormalities on high-resolution computed tomography (HRCT) are more pronounced in an A. fumigatus-colonized cohort compared with a matched non-Aspergillus-colonized CF group, a finding not reflected by pulmonary function testing alone (12) . A. fumigatus colonization has additionally been shown to be an independent risk factor for hospital admission in CF (1, 13) , yet studies assessing the effect of eradication of A. fumigatus from the CF airway unaffected by ABPA are limited. Although work on azole-based agents (e.g., itraconazole or voriconazole) in CF-ABPA is ongoing, the antiinflammatory effects of vitamin D and other VDR agonists in the setting of A. fumigatus colonization without ABPA remain unaddressed. This study clarifies the effect of A. fumigatus on VDR expression in the CF airway and for the first time evaluates treatment effectiveness of itraconazole in A. fumigatus colonization without ABPA. Some of the results of these studies have been previously reported in the form of an abstract (14) (15) (16) .
METHODS

Patient Selection and Recruitment
All patients with CF attending Beaumont Hospital, Dublin, Ireland, between July 2008 and June 2010 (2-yr period) were screened for study eligibility (n ¼ 117) (see Figure E1 in the online supplement). Inclusion criteria required a confirmed diagnosis of CF by sweat chloride concentrations greater than 60 mmol/l on at least two separate occasions and subsequent confirmatory genotyping. Patients included had to be colonized with A. fumigatus. Colonization was defined as detection of the fungus in sputum and/or bronchoalveolar lavage fluid (BALF) on at least two separate and consecutive occasions at least 12 weeks apart in the year before study commencement. Before recruitment, patients had to be exacerbation free over the preceding 6-week period with no prior diagnosis of ABPA (as per classical consensus conference criteria) (17) . Exclusion criteria included allergies to any azole related substances, prior lung transplantation, and either a confirmed or suspected diagnosis of ABPA or prior administration of systemic corticosteroid therapy in any form. All participants had serum IgE levels less than 450 ng/ml and negative cutaneous reactivity to Aspergillus antigens before the start of the study. Ethical approval from Beaumont Hospital Institutional Review Board was acquired, and written informed consent was obtained from all study participants during the screening/baseline (pretreatment) visit ( Figure E1 ). Demographics of recruited patients (n ¼ 13) are outlined in Table E1 in the online supplement. CT imaging, pulmonary function testing, Cystic Fibrosis Questionnaire Revised (CFQ-R) respiratory scoring, and observational study protocols are outlined in the online supplement.
Sputum, Bronchoalveolar Lavage, and Bronchial Brushing Samples
Spontaneously expectorated sputum from a deep cough was collected at each study visit. Sputum was divided into two sterile containers and transported immediately for evaluation. Suitability of sputum samples for study inclusion was confirmed by the criteria used to determine representative sputum samples (3). A single patient was a nonproducer; hence, BALF was used instead and obtained by standard methods (18) . A total of four samples per patient were obtained and processed over the 1-year study course (52 samples). Bronchial brushings were also obtained before and after itraconazole treatment (n ¼ 3) from A. fumigatus-positive or A. fumigatus -negative patients (n ¼ 3) not on treatment (age in years 6 SD, 24. 33 6 4.45 ; gender [% male/female], 50:50; FEV 1 % predicted 6 SD, 38.83 6 13.37; BMI 6 SD, 20.95 6 1.84; plasma vitamin D levels 6 SD, 47.66 6 26.31 ng/ml) and processed as previously described (19) . A full description of the procedures pertaining to the bronchial brushings can be found in the online supplement.
For processing of CF sputum or BALF for A. fumigatus colonization, an equal volume of Sputasol (Oxoid Ltd, Basingstoke, UK) was added to each sputum sample (no Sputasol was added to BALF), which was then shaken for 15 minutes at 37 8 C. The A. fumigatus status of homogenized sputum or BALF from each patient sample was determined in triplicate as colony forming units (CFU), and the concurrent equivalent number of conidia per gram of sputum as evaluated (a full protocol can be found in the online supplement). The occurrence of airway colonizers (e.g., P. aeruginosa and Staphylococcus aureus) were identified by standard microbiological methods as outlined by the Cystic Fibrosis Trust (20) . In vitro cell culture, preparation of Aspergillus culture supernatants, and treatment of human bronchial epithelial cells or macrophages is described in the online supplement.
Statistical Analysis
Descriptive analyses are presented as means (6 SD or SE), medians, or proportions depending on whether the data were normal, nonnormal, or categorical. Continuous data were tested for normality (Kolmogorov-Smirnoff or Shapiro Wilk tests as appropriate) and where normal were compared using a Student t test (paired or unpaired where appropriate). For nonnormal data, the Mann-Whitney U test was performed for comparisons. Tests for trends over time were conducted using repeated measures ANOVA for normally distributed data, and post hoc multiple comparison tests (Tukey's test) were applied. Friedmans chi-square test was used to compare trends over time for nonnormal (nonparametric) data. For count data (e.g., number of infective exacerbations), log-linear (poisson) regression analysis was performed using Generalized Estimating Equations for repeated measures within each patient. All statistical analyses were performed using the PRISM 4.0 software package (GraphPad, San Diego, CA) and SAS (v9.1; SAS Institute Inc., Cary, NC). Differences were considered significant at P < 0.05.
RESULTS
The Effect of A. fumigatus Culture Filtrates on VDR Gene and Protein Expression in CF Tracheal Epithelial and CF Bronchial Epithelial Cells
We and others have previously shown that A. fumigatus colonization affects approximately one third of people with CF (5, 6) , an observation further confirmed in this study ( Figure E1 ). The percentages of dominant immune cells in A. fumigatuscolonized CF BALF has been previously reported to include neutrophils (61%) and macrophages (31%) and, to a much lower extent, lymphocytes (4%) (21) . By Western blotting, however, VDR protein expression was found abundant in macrophages but not in neutrophils and at a very low level in T cells ( Figure E2 ). CF airway epithelial cells were also found to express VDR protein, and consequently this study examined the effect of A. fumigatus on VDR expression by structural (bronchial and tracheal epithelial cells) and immune cells (macrophages) of the airways.
VDR gene expression was significantly down-regulated by approximately 80% in CF tracheal epithelial (CFTE) cells (P ¼ 0.001) ( Figure 1A ) and was completely inhibited in CF bronchial epithelial (CFBE) cells (P ¼ 0.04) ( Figure 1B ) in response to treatment with 3-day culture filtrates for 16 hours. VDR gene expression was decreased by approximately 33% 2 hours after addition of Aspergillus culture filtrate in CFTE cells ( Figure 1C ) and was significantly down-regulated in CFTE and CFBE cells by approximately 50% after 5 hours of exposure to 3-day cultures (P ¼ 0.04) ( Figures 1C and 1D , respectively). Maximal effect was observed by treating CFBE cells with 4-day fungal culture filtrates for 5 hours, with total elimination of VDR gene expression observed (P ¼ 0.04) ( Figure  1E ).
The effect of A. fumigatus culture filtrates (1-4 d) on VDR protein expression was evaluated by Western blotting. Significant down-regulation of VDR protein expression was observed in CFTE and CFBE cells after treatment with 4-day culture filtrates for 5 hours (P ¼ 0.01 and P ¼ 0.009, respectively) ( Figures 1F and 1G ). To confirm the effect of Aspergillus colonization on VDR gene expression in vivo, bronchial brushings were performed on Aspergillus-positive (Asp 1 ; n ¼ 3) and Aspergillus-negative (Asp 2 ; n ¼ 3) patients. qRT-PCR confirmed significant down-regulation of VDR gene expression in vivo in Aspergillus-colonized patients, in line with in vitro results (P ¼ 0.02) ( Figure 1H ). Collectively these results indicate in vitro and in vivo down-regulation of VDR gene and protein expression by A. fumigatus.
Down-regulation of VDR Expression by Gliotoxin, an Immunomodulatory Mycotoxin from A. fumigatus
The VDR modulator present within culture filtrates of A. fumigatus (ATCC 26933) was characterized. The inhibitory activity was stable within culture filtrates stored at 270 8 C and subsequently used against CFBE cells at 37 8 C but was significantly abolished by heat inactivation (99 8 C) for 20 minutes (P ¼ 0.003) ( Figure 2A ). Passage of culture filtrates through a 3 kD exclusion filter removed approximately 65% of the VDR inhibitory activity (P ¼ 0.007), which suggested the presence of predominantly low-molecular-weight (, 3 kD) VDR inhibitory factors.
Secreted by the hyphal form of A. fumigatus, gliotoxin (Gt) has previously been characterized as a small, heat-inactivated toxin of 326.4 daltons (22) . Gt has been shown to provoke airway inflammation and tissue damage with consequential longterm airway remodeling (23) . To confirm Gt as a fungal agent capable of VDR down-regulation, the effect of a low-Gtproducing A. fumigatus strain (CaF1) on VDR expression was explored. Strain CaF1 produced minimal levels of Gt compared with the high-Gt-producing strain ATCC-26933 after 96 hours of fungal growth (2 6 0.05 and 252 6 2.5 ng/mg hyphae, respectively) ( Figure E3 ). Moreover, VDR expression in CFTE and CFBE cells remained relatively unchanged when treated with 1to 4-day culture filtrates of CaF1, in comparison to the ATCC-26933 strain, which resulted in significant down-regulation of VDR (P ¼ 0.01 and P ¼ 0.009 for CFTE and CFBE cells compared with untreated cells, respectively) ( Figures 2C and 2D ). The clinical relevance of these findings was confirmed when BALF obtained from Aspergillus-positive patients illustrated high levels of Gt, as quantified by HPLC analysis of chloroform extracts ( Figure 2E ).
The effect of purified Gt on VDR expression by CF and non-CF cells was next explored. By HPLC analysis of cultures of A. fumigatus strain ATCC-26933, no significant difference was detected in Gt levels produced on Day 3 (280 6 29 ng/mg hyphae) compared with Day 4 (252 6 2.5 ng/mg hyphae) (P . 0.05) ( Figure E3A ). This concentration produced by the fungus equates to approximately 0.8 mM commercial Gt, which was therefore used in this study. Gt used at this concentration significantly down-regulated VDR protein expression in CFBE Figure 1 . Culture filtrates of Aspergillus fumigatus down-regulate vitamin D receptor (VDR) gene and protein expression. Cystic fibrosis tracheal epithelial (CFTE) (A and C) and cystic fibrosis bronchial epithelial (CFBE) (B and D) cells (1 3 10 5 ) were untreated (Con) or treated with 3 days of A. fumigatus (ATCC-26933) culture filtrates (AFCF) for 16 hours (A and B) or 0 to 5 hours (C and D). RNA was isolated and analyzed for VDR gene expression by qRT-PCR and standardized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). VDR gene expression was significantly down-regulated at 16 hours and at the earlier time point of 5 hours after treatment (C and D). CFBE cells were treated for 5 hours with 4-day fungal culture filtrates, with total downregulation of VDR gene expression observed (E ). (F and G) Western blot analysis of VDR protein expression of CFTE (F) and CFBE (G) cells (1 3 10 6 ) treated with AFCF (0-to 4-d cultures). Western blots were probed with mouse monoclonal VDR or rabbit polyclonal GAPDH (loading control) antibodies. The Western blot illustrated is a representative result of one out of three separate experiments and converted to densitometry units in respective graphs. VDR protein expression was significantly down-regulated by 4day cultures. (H) Bronchial brushings were obtained from subjects with CF who were positive (Asp1) (n ¼ 3) and negative (Asp2) (n ¼ 3) for Aspergillus colonization and analyzed for VDR gene expression by qRT-PCR. VDR gene expression was significantly down-regulated in subjects with CF colonized with Aspergillus compared with those noncolonized by Aspergillus. All experiments were performed in triplicate on three consecutive days. Data shown are mean 6 SE. cells (P ¼ 0.03) to a similar level obtained after exposure to 4-day culture filtrates of A. fumigatus (ATCC-26933), indicating that Gt is most likely the main VDR inhibitory factor secreted by the fungus (Figure E3B ).
In vitro studies further revealed that 0.8 mM Gt significantly down-regulated VDR gene expression in CFTE (P ¼ 0.001), (D) or air-liquid interface (5 3 10 5 ) (E) or U937 differentiated macrophages (1 3 10 6 ) (F) were untreated (Con) or exposed to 1,25D 3 (10 29 M) in the presence or absence of Gt (0.8 mM) for 24 hours, and VDR protein expression was analyzed by Western blotting using mouse monoclonal VDR and rabbit polyclonal GAPDH antibodies. All assays were standardized to GAPDH and were performed in triplicate on three separate days. Data shown are mean 6 SE. 3E) treated with 1,25D 3 in the presence of 0.8 mM Gt exhibited significant down-regulation of VDR protein expression compared with cells treated with 1,25D 3 only (P ¼ 0.04 and P ¼ 0.005, respectively). This effect was also observed by treating macrophages with Gt (P ¼ 0.03) ( Figure 3F ). Control experiments indicated that Gt did not affect cell viability or induce cell apoptosis as determined by trypan blue exclusion assays or a lack of cleaved (17/19 kD) caspase-3, respectively (result not shown). Collectively these experiments suggest an overwhelming inhibitory effect of Gt on VDR expression.
Gliotoxin Enhances the Production of Th2 Cytokines, Which Are Reduced after Itraconazole Treatment It has been shown that VDR knockout mice have elevated levels of IL-5 and IL-13 production (10), and vitamin D has also been observed to modulate Aspergillus-induced Th2 cytokines IL-5 and IL-13 expression in CD4 1 T cells (9) . In line with this, we investigated the effect of Gt on IL-5 and IL-13 expression in vitro. Figures 4E and 4F ). In support of this result, high levels of IL-5 and IL-13 were observed in CF BALF samples before itraconazole treatment (Figures 4G and 4H) . After itraconazole treatment, a significant decrease in IL-5 (P ¼ 0.01) and IL-13 (P ¼ 0.002) protein expression was detected in vivo, suggesting a role for itraconazole in reducing the Th2 inflammatory response in these patients.
Itraconazole Treatment Effectively Reduces A. fumigatus Bioburden in CF Airways
Itaconazole therapy administered orally at 400 mg once daily for a 6-week period significantly reduced A. fumigatus bioburden within the CF airway over time as determined by CFU and conidia counts per gram of sputum and/or BALF ( Figures 5A and  5B ). Itraconazole therapy was well tolerated in the study cohort, with no reports of adverse effects or liver dysfunction during treatment and follow-up. Although CFU counts remained low at the 12-month follow-up ( Figure 5A ), A. fumigatus conidia burden was increased when compared with the 6-month followup sample ( Figure 5B ), suggesting that qPCR is a more reliable method of Aspergillus detection in CF sputum. In addition, corresponding to a reduction in Aspergillus bioburden at the 12month follow-up, levels of Gt were significantly reduced in vivo from approximately 250 6 80 to 75 6 50 ng/mg BALF protein (P ¼ 0.04) ( Figure 5C ). Moreover, after 6 weeks of itraconazole (400 mg daily) treatment for Aspergillus infection, VDR gene expression was significantly increased by greater than 2-fold (P ¼ 0.04) ( Figure 5D ). This set of experiments demonstrates that itraconazole therapy significantly reduced A. fumigatus colonization within the CF airways and by corollary diminished Gt levels initiating up-regulation of VDR expression.
A. fumigatus Is Associated with a Mosaic Pattern on HRCT That Significantly Attenuates after Itraconazole Therapy
It has been shown that A. fumigatus colonization in CF has adverse effects upon the lung parenchyma (on HRCT) that do not correlate with pulmonary function testing (12) . To establish the presence of radiological changes after eradication of A. fumigatus from the CF airway, HRCT scans were performed (A and B) , CFBE cells grown under air liquid conditions (5 3 10 5 ) (C and D), and U937 differentiated macrophages (1 3 10 6 ) (E and F) were untreated (Con) or exposed to Gt (0.8 mM) alone or to 1,25D 3 (10 29 M) in the presence or absence of Gt for 24 hours. IL-5 (A) or IL-13 (B) gene expression was analyzed by qRT-PCR and standardized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). IL-5 (C and E) or IL-13 (D and F) protein expression was quantified by ELISA. Assays were performed in triplicate on three separate days. (G and H) IL-5 and IL-13 in vivo cytokine expression is reduced after itraconazole treatment. IL-5 (G) and IL-13 (H) levels in healthy control subjects (n ¼ 3, Con) and in Aspergillus-positive cystic fibrosis bronchoalveolar lavage (BALF) before (n ¼ 3) or after itraconazole treatment (n ¼ 3) were quantified by ELISA. Assays illustrated in C and D were performed a minimum of three times in duplicate and normalized to total BALF protein. Data shown are mean 6 SE.
in people with CF colonized by A. fumigatus with no prior history of ABPA or corticosteroid treatment for suspected ABPA (n ¼ 13). Three HRCT scans were performed at baseline (pretreatment), at 10 weeks after completion of itraconazole (posttreatment), and at 12-month follow-up.
No significant differences in the overall or component parts of the modified Bhalla score was identified after treatment or during follow-up. However, 92.3% (n ¼ 12) of baseline (pretreatment) scans illustrated a mosaic pattern, which was significantly less evident after itraconazole eradication of A. fumigatus. Fewer scans after treatment (76.9%; n ¼ 10) or during follow-up (53.8%; n ¼ 7) illustrated evidence of the mosaic pattern observed at baseline ( Figures 6A and 6B ). In patients in whom attenuation rather than elimination of the pattern occurred after itraconazole treatment, we further quantified the mosaic pattern by its conspicuity (obvious, subtle, or present on expiratory images only) and by percentage of lung parenchyma involved. A significantly diminished conspicuity and a lower percentage of lower lobe lung parenchymal involvement after treatment and during follow-up was observed ( Figure 6C ).
Pulmonary function (FEV 1 and forced expiratory flow, midexpiratory phase [FEF ]) remained stable without significant deterioration over the study course ( Figure 6D ). However, eradication of A. fumigatus from the CF airway resulted in a significant reduction in the number of infective exacerbations ( Figure 6E ) and requirement for intravenous antibiotic therapy ( Figure E4) , findings that were sustained over the study follow-up period. Respiratory symptoms (assessed by CFQ-R) illustrated significant improvement during follow-up that was maintained to study conclusion ( Figure 6F ). Additionally, mean serum levels of IgE decreased after treatment (178.2 6 88.4 to 136.9 6 60.7 IU/ml) and during follow-up (90.5 6 32.0 IU/ml), albeit not significantly (P . 0.05). No patient developed ABPA over the course of the study. Radioallergosorbent test Aspergillus sampling validated this. In summary, these results indicate that eradication of A. fumigatus from the CF airway resulted in improved HRCT appearances, less infective exacerbations, fewer requirements for intravenous antibiotics, and improved CFQ-R respiratory symptom scores.
DISCUSSION
In the current study, we illustrate that A. fumigatus colonization down-regulates VDR and identify Gt as one fungal agent responsible for mediating this effect. We also found that in vivo A. fumigatus colonization is associated with increased Gt in CF BALF, mosaic pattern on HRCT, and an enhanced production of the Th2 cytokines IL-5 and IL-13. Treatment with the antifungal agent itraconazole in vivo rescued VDR expression, significantly attenuated Gt levels, and decreased the production of the Th2 cytokines IL-5 and IL-13, which drive the allergic process leading to ABPA (24, 25) . Such eradication of A. fumigatus from the CF airway resulted in improved respiratory symptoms and diminished HRCT mosaic pattern, consistent with sustained pulmonary function.
Vitamin D influences the inflammatory and immune state in CF and acts via cognate nuclear VDR (26, 27) . Although insufficient vitamin D (, 30 ng/ml) is problematic for bone health in CF, it is also acknowledged as a risk factor for ABPA in those colonized with A. fumigatus (9, 28) . Consequently, supplemental administration of vitamin D is advocated for its potential to prevent ABPA (9) . As a result, the protein level of VDR through which vitamin D functions is clinically relevant but has not been investigated thoroughly in the context of CF complicated by A. fumigatus. In this study, we illustrate that A. fumigatus colonization in the absence of ABPA down-regulates VDR and enhances Th2 cytokine production through Gt, a toxin released by the hyphal form of the fungi. Compromised VDR in the face of A. fumigatus disrupts the inflammatory state in CF, with vitamin D unable to exert its positive impact. One method by which Figure 5 . Aspergillus bioburden is significantly reduced in the cystic fibrosis (CF) lung after itraconazole therapy, resulting in increased vitamin D receptor (VDR) expression. (A) Colony-forming units (CFU) of A. fumigatus per gram of spontaneously expectorated sputum were determined in subjects with CF (n ¼ 13) before (Pre) and after (Post) treatment with itraconazole (400 mg orally once daily for 6 wk) and at 6 and 12 months. All CFU counts were performed in triplicate for each patient sample. **P , 0.001 (Friedman's test; Q ¼ 20.59). (B) The equivalent A. fumigatus conidia number was determined in the same patient group (n ¼ 13) using qPCR and A. fumigatus primer probe sets targeting the 28S rRNA region. DNA extraction for each patient sample was performed in duplicate, and qPCR was performed at least in triplicate. **P , 0.01 (Friedman's test; Q ¼ 15.12). (C) Gliotoxin (Gt) levels in vivo are reduced as a consequence of itraconazole treatment. Gt levels were quantified in cystic fibrosis bronchoalveolar lavage (BALF) before (n ¼ 3) or after itraconazole treatment (n ¼ 3) by HPLC and normalized to total BALF protein (mg) and analyzed by paired t test. (D) After itraconazole treatment, VDR gene expression is upregulated in Aspergillus-colonized patients in vivo. Bronchial brushings were obtained from people with cystic fibrosis before (n ¼ 3) or after itraconazole treatment (n ¼ 3), and VDR gene expression was analyzed by qRT-PCR standardized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The assay was performed in triplicate. Data shown are the mean 6 SD (A and B) or 6 SE (C and D).
vitamin D confers benefit is by attenuating Th2 responses to A. fumigatus by CD41 T cells in CF-ABPA (9) . Th2 cytokines IL-5 and IL-13 are not restricted to CD41 cells alone, and, although this source remains of primary concern in the ABPA context, release of these cytokines by eosinophil and mast cells (29, 30) , and by airway epithelial cells and macrophages as shown in the present study, is of importance in people with CF colonized by A. fumigatus but unaffected by ABPA.
The unique structural motif of Gt is essential for its damaging effects, including the inhibition of immune cell activation, phagocytosis, and ciliary beat frequency, together preventing fungal clearance (22, 31, 32) . Gt concentrations have been reported in the setting of a murine model of invasive aspergillosis (33) ; however, to our knowledge this is the first study to report Gt levels in vivo in the context of CF and its relationship to VDR expression. However, Gt-mediated VDR down-regulation is independent of CFTR dysfunction; this phenomenon was observed during in vitro experiments using non-CF HBE cells.
Gt is also able to overcome the positive effects conferred by vitamin D on VDR expression, a novel mode of action within the pulmonary milieu. Placing our findings in the context of those reported by Kriendler and colleagues (9) , vitamin D may attenuate Th2 cytokines and potentially reduce or prevent CF-ABPA, although it requires the presence of VDR to carry out such functions. Hence, the elimination of Gt remains as crucial as the administration of vitamin D.
This observational study provided unique insights into the treatment effectiveness of itraconazole on microbiological, radiological, and clinical outcomes, the former two not addressed by prior work (34) . Sputum culture alone has been previously reported as insufficient at detecting the presence of A. fumigatus in CF (6, 35) . Despite this, CFU counts for A. fumigatus remain the most accessible and affordable method of assessment and therefore remain in routine clinical practice. Failure to detect A. fumigatus because of a negative sputum culture can have deleterious clinical consequences. In view of this, we chose to assess for the presence of A. fumigatus from sputum using two separate approaches, CFU counts and qPCR for A. fumigatus conidia burden. Although itraconazole was effective at eliminating A. fumigatus after treatment, these effects were sustained over the 1-year follow-up by both methodologies. However, despite the reassuring CFU counts obtained at the 1-year time point, escalations of A. fumigatus conidia burden were detectable by qPCR at this time as compared with earlier time points, suggesting a slow return of A. fumigatus colonization and the potential need for retreatment. These data provide evidence to support use of qPCR as the optimal detection method for A. fumigatus from respiratory CF samples. However, the clinical parameters assessed in this study continue to show positive effects at 12 months after treatment, a time when qPCR counts for A. fumigatus conidia begin to slowly rise (35) . Consequently, cost and clinical importance of such methods for A. fumigatus detection must be considered before recommending their routine use. Most benefit from such methodology is probably gained from its use in clinical scenarios of strongly suspected A. fumigatus-associated disease in the presence of negative sputum culture where a treatment decision is necessary and further microbiological evidence for such treatment is sought. This may be applicable to A. fumigatus beyond CF.
Further work performed by our group described the radiological evaluation of A. fumigatus colonization in CF (12) and reported a novel mosaic pattern associated with such colonization in the CF setting unrelated to ABPA. Quantification of this mosaic pattern over the study course and after itraconazole treatment illustrated elimination or significant attenuation, suggestive of an inflammatory benefit in the individuals with CF recruited to this study. Significant time-dependent effects, greatest at 12-month follow-up, were observed. Whether such findings confer prolonged benefit or represent a radiological lag in appearance compared with clinical benefit remains to be elucidated. Although images from an untreated placebo controlled group of A. fumigatus colonized patients with CF without ABPA would have provided stronger evidence for this radiological relationship, we feel it would have been unethical to recruit an untreated group in view of our previously published work illustrating worse radiological appearances in patients who are A. fumigatus colonized (12) . Although our study findings are of interest, the small study population and the uncontrolled and open-label nature of the trial are notable weaknesses. However, itraconazole treatment produced positive outcomes across all the clinical parameters assessed, including decreasing exacerbations and stabilizing pulmonary function while improving CFQ-R respiratory scores, findings contrasting prior work (34) . Moreover, itraconazole is a potent inhibitor of CYP3A4 activity, and corticosteroids are partly metabolized through such enzymes; hence, it should be noted that a proportion of our patient cohort received inhaled corticosteroids at a low dose during the course of the study (Table E1 ). Systemic absorption of such steroid use is accepted to be diminutive; hence, the effects on the CYP3A4 system conferred by itraconazole treatment during the study are probably minimal. However, this is a potential confounding factor to be considered when interpreting our results. No patient during the study developed ABPA by consensus criteria (17) , and a reduced likelihood of ABPA occurring was demonstrated by decreasing levels of IgE, radioallergosorbent test to Aspergillus, and an attenuated Th2 cytokine response after treatment.
Despite the fact that IL-5 and IL-13 are linked to ABPA, none of the patients recruited to this study had ever had ABPA, although high levels of these cytokines were present in their lungs. These Th2 cytokines were significantly reduced after itraconazole therapy, which is suggestive of an important antiinflammatory role for the drug in addition to its antifungal properties. Minimal clinical data exist within the CF literature to assist the clinician in identifying individuals at risk of ABPA or those that can be predicted to develop ABPA in the setting of A. fumigatus colonization alone. Although our group has previously shown that sputum isolation of A. fumigatus does not correlate with occurrence of ABPA (6), the current study has uncovered high levels of Th2 cytokines IL-5 and IL-13 existing in vivo in the setting of A. fumigatus colonization without ABPA that may be attenuated by empirical itraconazole treatment. Whether such therapy can prevent ABPA in the long term in those asymptomatically colonized by A. fumigatus remains to be determined.
In summary, although published work has suggested the therapeutic potential of vitamin D in preventing ABPA (9) , our data imply that this approach is only feasible with concurrent elimination of A. fumigatus with itraconazole to permit VDR expression. This study raises awareness of the clinical importance of antifungal resistance (36, 37) and acknowledges the need for a more long-term study on the antifungal activity of triazole derivatives in the treatment of A. fumigatus in individuals with CF.
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